November 2023

June 2021

Press Release: Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer

2026-01-07T11:39:35-06:00June 8th, 2021|Press Release|

June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments

Read More

The Vanquish® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.

Federal law (USA) restricts this device to sale by or on the order of a physician.

Refer to the device User Manual for a list of contraindications, warnings, and cautions.

Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.

1. Taneja, S., George, A, (2025, October 9-11). Thermal Water Therapy for The Management of Prostate Cancer: The VAPOR 2 Study: Initial Report Poster]. FOCAL+ Therapy Conference, Washington, DC, United States. https://focalcme.com/

© Copyright Francis Medical, Inc. 2025 | Part Number 4723-029_03 12 JAN 2026 | ALL RIGHTS RESERVED

Go to Top